Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GABRIEL PARDO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1215969605
CMS profile
237132
Location
OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$185,420.09

290 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GABRIEL PARDO

NPI 1215969605 · CMS profile ID 237132

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215969605?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GABRIEL PARDO, NPI 1215969605, CMS profile ID 237132. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215969605?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). GABRIEL PARDO, NPI 1215969605, CMS profile ID 237132. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215969605?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
GABRIEL PARDO, NPI 1215969605, CMS profile ID 237132, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 290 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215969605?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

290 matching records · $185,420.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 290 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 290.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $4,500.0009/14/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708853269 CMS
Novartis Pharmaceuticals Corporation $98.9509/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827871 CMS
Novartis Pharmaceuticals Corporation $39.2409/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827931 CMS
Novartis Pharmaceuticals Corporation $87.4409/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827875 CMS
Supernus Pharmaceuticals, Inc. $16.3509/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702341709 CMS
Avanir Pharmaceuticals, Inc. $11.9608/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653613683 CMS
Biogen, Inc. $77.2908/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619883 CMS
Biogen, Inc. $13.2708/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619919 CMS
Genentech USA, Inc. $24.2908/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681365409 CMS
Genentech USA, Inc. $120.6408/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681408393 CMS
Genentech USA, Inc. $4,800.0008/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681411193 CMS
Novartis Pharmaceuticals Corporation $119.8408/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827927 CMS
Novartis Pharmaceuticals Corporation $24.6508/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827929 CMS
Genentech USA, Inc. $23.5508/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681359555 CMS
EMD Serono, Inc. $18.9708/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702975661 CMS
Supernus Pharmaceuticals, Inc. $4.8508/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702341707 CMS
Medtronic USA, Inc. $19.3808/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667707753 CMS
Biogen, Inc. $2,362.5008/14/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619861 CMS
GENZYME CORPORATION $18.9308/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694145901 CMS
Biogen, Inc. $10,500.0008/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619935 CMS
Biogen, Inc. $11.6008/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619871 CMS
Biogen, Inc. $10.1608/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619873 CMS
Biogen, Inc. $36.0008/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619875 CMS
Biogen, Inc. $6.5008/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619881 CMS
Biogen, Inc. $428.5108/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619863 CMS
Biogen, Inc. $838.0308/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619867 CMS
Biogen, Inc. $8,400.0008/10/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619877 CMS
Biogen, Inc. $20.0008/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619879 CMS
Biogen, Inc. $9.5808/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619865 CMS
Biogen, Inc. $11.6008/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660619869 CMS
GENZYME CORPORATION $121.2608/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694269237 CMS
GENZYME CORPORATION $3,920.0008/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694269243 CMS
GENZYME CORPORATION $124.1208/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694269253 CMS
EMD Serono, Inc. $23.7808/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702967569 CMS
Supernus Pharmaceuticals, Inc. $9.4708/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702341705 CMS
Novartis Pharmaceuticals Corporation $5.5608/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827889 CMS
Novartis Pharmaceuticals Corporation $873.5808/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827921 CMS
Novartis Pharmaceuticals Corporation $3,192.0008/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827923 CMS
Novartis Pharmaceuticals Corporation $114.9908/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827925 CMS
GENZYME CORPORATION $31.2207/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694158219 CMS
Novartis Pharmaceuticals Corporation $16.2407/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827909 CMS
Novartis Pharmaceuticals Corporation $2,660.0007/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827911 CMS
Novartis Pharmaceuticals Corporation $121.0007/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659827913 CMS
Mallinckrodt Enterprises LLC $11.7907/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704759965 CMS
Mallinckrodt Enterprises LLC $119.5807/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704759967 CMS
EMD Serono, Inc. $7.5807/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703012855 CMS
Supernus Pharmaceuticals, Inc. $7.5007/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702341703 CMS
Mallinckrodt Enterprises LLC $0.6307/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704759961 CMS
Mallinckrodt Enterprises LLC $28.9307/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704759963 CMS
EMD Serono, Inc. $7.0507/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703013471 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $185,420.09 290
PY2020 $108,071.23 97
PY2021 $110,573.48 89
PY2022 $197,474.08 188
PY2023 $312,698.93 261
PY2024 $226,679.22 263
PY2025 $311,505.44 326

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,274.95 2
PY2025 Principal investigator $1,360,450.47 131
PY2024 Recipient $4,639.65 3
PY2024 Principal investigator $1,762,830.96 87
PY2023 Principal investigator $1,247,325.52 86
PY2022 Principal investigator $1,192,067.64 79
PY2021 Recipient $15,446.80 7
PY2021 Principal investigator $940,955.68 126
PY2020 Recipient $17,062.29 15
PY2020 Principal investigator $1,303,603.39 128
PY2019 Recipient $1,728.14 5
PY2019 Principal investigator $992,686.48 136

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

133 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $1,362.20 12/09/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198843
Principal investigator 1 F. Hoffmann-La Roche AG $276.00 12/08/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211634381
Principal investigator 1 F. Hoffmann-La Roche AG $2,000.00 12/08/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211634385
Principal investigator 1 TG Therapeutics, Inc. $800.58 12/03/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198839
Principal investigator 1 Genentech, Inc. $1,929.00 11/25/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211634463
Principal investigator 1 Genentech, Inc. $7,032.53 11/05/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211634458
Principal investigator 1 TG Therapeutics, Inc. $1,279.25 11/01/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198841
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198685
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198687
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198689
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198691
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198693
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198845
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198847
Principal investigator 1 TG Therapeutics, Inc. $1,750.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198849
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198851
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198853
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198855
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198857
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198859
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 10/27/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198861
Principal investigator 1 TG Therapeutics, Inc. $2,668.60 10/23/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198837
Principal investigator 1 ModernaTX, Inc. $10,500.00 10/16/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252958225
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/16/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252958231
Principal investigator 1 ModernaTX, Inc. $3,750.00 10/16/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252958233
Principal investigator 1 Novartis Pharmaceuticals Corporation $477.74 10/08/2025 Non-covered Recipient Entity
MULTIPLE SCLEROSIS CENTER OF EXCELLENCE OF OMRF
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190307589
Principal investigator 1 Novartis Pharmaceuticals Corporation $69,984.64 10/01/2025 Non-covered Recipient Entity
MULTIPLE SCLEROSIS CENTER OF EXCELLENCE OF OMRF CFTY720D2399E1
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190306493
Principal investigator 1 TG Therapeutics, Inc. $14,421.25 09/30/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198833
Principal investigator 1 Genentech, Inc. $6,629.00 09/18/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211634443
Principal investigator 1 F. Hoffmann-La Roche AG $3,385.00 09/15/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211634368
Principal investigator 1 F. Hoffmann-La Roche AG $3,385.00 09/15/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211634372
Principal investigator 1 F. Hoffmann-La Roche AG $309.00 09/15/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211634375
Principal investigator 1 TG Therapeutics, Inc. $21,927.10 08/31/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198831
Principal investigator 1 Genentech, Inc. $4,400.00 08/26/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211634413
Principal investigator 1 Genentech, Inc. $1,800.00 08/22/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211634438
Principal investigator 1 Genentech, Inc. $2,400.00 08/22/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211634455
Principal investigator 1 Genentech, Inc. $2,403.00 08/21/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211634450
Principal investigator 1 Genentech, Inc. $3,021.00 08/15/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211634417
Principal investigator 1 Genentech, Inc. $1,500.00 08/06/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211634433
Principal investigator 1 TG Therapeutics, Inc. $4,878.10 07/31/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198829
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 07/31/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198835
Principal investigator 1 GENZYME CORPORATION $13,300.00 07/28/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226120368
Principal investigator 1 GENZYME CORPORATION $24,244.70 07/28/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226120370
Principal investigator 1 GENZYME CORPORATION $900.00 07/02/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226120365
Principal investigator 1 Genentech, Inc. $4,925.00 06/17/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211634421
Principal investigator 1 TG Therapeutics, Inc. $3,500.00 06/16/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198735
Principal investigator 1 TG Therapeutics, Inc. $3,750.00 06/16/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198737
Principal investigator 1 TG Therapeutics, Inc. $535.00 06/16/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198739
Principal investigator 1 TG Therapeutics, Inc. $4,285.00 06/16/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198741
Principal investigator 1 TG Therapeutics, Inc. $2,009.00 06/16/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198743
Principal investigator 1 TG Therapeutics, Inc. $535.00 06/16/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198747
Principal investigator 1 TG Therapeutics, Inc. $535.00 06/16/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198775
Principal investigator 1 Genentech, Inc. $1,414.00 06/03/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211634404
Principal investigator 1 TG Therapeutics, Inc. $22,136.80 06/01/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198733
Principal investigator 1 ModernaTX, Inc. $118.00 05/29/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252958227
Principal investigator 1 ModernaTX, Inc. $66.24 05/29/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years No dispute reported 06/30/2026 1252958229
Principal investigator 1 TG Therapeutics, Inc. $885.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198721
Principal investigator 1 TG Therapeutics, Inc. $350.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198723
Principal investigator 1 TG Therapeutics, Inc. $700.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198725
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198727
Principal investigator 1 TG Therapeutics, Inc. $4,985.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198729
Principal investigator 1 TG Therapeutics, Inc. $500.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198731
Principal investigator 1 TG Therapeutics, Inc. $350.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198749
Principal investigator 1 TG Therapeutics, Inc. $885.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198751
Principal investigator 1 TG Therapeutics, Inc. $885.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198753
Principal investigator 1 TG Therapeutics, Inc. $700.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198755
Principal investigator 1 TG Therapeutics, Inc. $700.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198757
Principal investigator 1 TG Therapeutics, Inc. $700.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198759
Principal investigator 1 TG Therapeutics, Inc. $700.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198761
Principal investigator 1 TG Therapeutics, Inc. $350.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198763
Principal investigator 1 TG Therapeutics, Inc. $700.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198765
Principal investigator 1 TG Therapeutics, Inc. $4,985.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198767
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198769
Principal investigator 1 TG Therapeutics, Inc. $700.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198771
Principal investigator 1 TG Therapeutics, Inc. $500.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198773
Principal investigator 1 TG Therapeutics, Inc. $700.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198777
Principal investigator 1 TG Therapeutics, Inc. $700.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198815
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198817
Principal investigator 1 TG Therapeutics, Inc. $885.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198819
Principal investigator 1 TG Therapeutics, Inc. $700.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198821
Principal investigator 1 TG Therapeutics, Inc. $885.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198823
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 05/14/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198825
Principal investigator 1 TG Therapeutics, Inc. $4,386.00 05/01/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198711
Principal investigator 1 GENZYME CORPORATION $3,450.00 04/14/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226120360
Recipient Novartis Pharmaceuticals Corporation $2,969.27 04/10/2025 Covered Recipient Physician COMB157G2301,COMB157G2302,COMB157G2399,COMB157G2399 No dispute reported 06/30/2026 1190292279
Principal investigator 1 GENZYME CORPORATION $3,650.00 04/07/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226120353
Principal investigator 1 Genentech, Inc. $2,403.00 04/02/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211634429
Recipient F. Hoffmann-La Roche AG $305.68 03/31/2025 Covered Recipient Physician Ocrelizumab in Patients with RMS No dispute reported 06/30/2026 1211535842
Principal investigator 1 TG Therapeutics, Inc. $9,607.00 03/31/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198709
Principal investigator 1 F. Hoffmann-La Roche AG $9,227.00 03/21/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211634347
Principal investigator 1 F. Hoffmann-La Roche AG $3,593.00 03/21/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211634356
Principal investigator 1 F. Hoffmann-La Roche AG $9,227.00 03/21/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211634366
Principal investigator 1 GENZYME CORPORATION $2,070.00 03/17/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226120338
Principal investigator 1 GENZYME CORPORATION $16,624.00 03/17/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226120342
Principal investigator 1 GENZYME CORPORATION $3,450.00 03/17/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226120346
Principal investigator 1 GENZYME CORPORATION $20,465.00 03/17/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226120350
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 03/12/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211634360
Principal investigator 1 F. Hoffmann-La Roche AG $410.00 03/12/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211634363
Principal investigator 1 TG Therapeutics, Inc. $16,315.00 02/28/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198707
Principal investigator 1 Genentech, Inc. $1,414.00 02/20/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211634408
Principal investigator 1 Biogen, Inc. $29,239.44 02/19/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation
Comparison of Tysabri, Vumerity, and Ocrevus in MS Patients Stable on Therapy to Characterize Divergent Proteomic, Radiomic, and Clinical Trajectories No dispute reported 06/30/2026 1236947634
Principal investigator 1 F. Hoffmann-La Roche AG $9,019.00 02/19/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211634349
Principal investigator 1 Genentech, Inc. $2,403.00 02/14/2025 Non-covered Recipient Entity
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211634425
Principal investigator 1 TG Therapeutics, Inc. $12,008.70 02/12/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198745
Principal investigator 1 TG Therapeutics, Inc. $1,500.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198713
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198715
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198717
Principal investigator 1 TG Therapeutics, Inc. $500.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198719
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198779
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198781
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198783
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198785
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198787
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198789
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198791
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198793
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198795
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198797
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198799
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198801
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198803
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198805
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198807
Principal investigator 1 TG Therapeutics, Inc. $4,435.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198809
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198811
Principal investigator 1 TG Therapeutics, Inc. $4,250.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198813
Principal investigator 1 TG Therapeutics, Inc. $111,078.00 02/07/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198827
Principal investigator 1 GENZYME CORPORATION $13,900.00 02/04/2025 Non-covered Recipient Entity
Oklahoma Medical Research Foundation
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226120333
Principal investigator 1 TG Therapeutics, Inc. $9,343.00 01/31/2025 Non-covered Recipient Entity
OMRF MS CENTER OF EXCELLENCE
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198705
Principal investigator 1 Novartis Pharmaceuticals Corporation $45,277.06 01/06/2025 Non-covered Recipient Entity
MULTIPLE SCLEROSIS CENTER OF EXCELLENCE OF OMRF
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190307591
Principal investigator 1 Novartis Pharmaceuticals Corporation $48,547.47 01/06/2025 Non-covered Recipient Entity
MULTIPLE SCLEROSIS CENTER OF EXCELLENCE OF OMRF
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190307593
Principal investigator 1 Novartis Pharmaceuticals Corporation $72.00 01/01/2025 Non-covered Recipient Entity
MULTIPLE SCLEROSIS CENTER OF EXCELLENCE OF OMRF CFTY720D2399E1
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy No dispute reported 06/30/2026 1190306491
Principal investigator 1 Novartis Pharmaceuticals Corporation $525,178.03 01/01/2025 Non-covered Recipient Entity
MULTIPLE SCLEROSIS CENTER OF EXCELLENCE OF OMRF CFTY720D2399E1
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190306495